IONIS PHARMACEUTICALS, INC.
- Country
- ๐บ๐ธUnited States
- Ownership
- Public, Private, Subsidiary
- Established
- 1989-01-01
- Employees
- 927
- Market Cap
- -
- Website
- http://www.ionis.fr
ISIS 2302-CS22, A 6-Week, Active-Controlled Clinical Study to Evaluate the Effectiveness of Alicaforsen (ISIS 2302) in Patients With Mild to Moderate Active Ulcerative Colitis
- Conditions
- First Posted Date
- 2003-06-27
- Last Posted Date
- 2022-12-05
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Registration Number
- NCT00063414
Addition of ISIS 14803 to Therapy With Peginterferon and Ribavirin for Chronic Hepatitis C (HCV) Patients Not Responding Adequately to the Two Drugs
- Conditions
- First Posted Date
- 2003-06-18
- Last Posted Date
- 2022-12-05
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT00062816
- Locations
- ๐บ๐ธ
University of Florida, Jacksonville, Florida, United States
๐บ๐ธWilliam Beaumont Hospital, Royal Oak, Michigan, United States
๐บ๐ธBaylor College of Medicine-VAMC, Houston, Texas, United States
ISIS 104838, an Inhibitor of Tumor Necrosis Factor, for Active Rheumatoid Arthritis
- Conditions
- First Posted Date
- 2002-10-31
- Last Posted Date
- 2022-12-05
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 160
- Registration Number
- NCT00048321
Alicaforsen (ISIS 2302) in Patients With Active Crohn's Disease
- Conditions
- First Posted Date
- 2002-10-30
- Last Posted Date
- 2022-08-15
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT00048295
Alicaforsen (ISIS 2302) in Patients With Active Crohn's Disease
- Conditions
- First Posted Date
- 2002-10-25
- Last Posted Date
- 2022-12-05
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT00048113
ISIS 14803-CS2, Treatment With ISIS 14803, Administered IV in Patients With Chronic Hepatitis C Virus Infections
- Conditions
- First Posted Date
- 2002-05-08
- Last Posted Date
- 2022-12-05
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Registration Number
- NCT00035945
- Locations
- ๐บ๐ธ
Isis Pharmaceuticals, Carlsbad, California, United States
The Safety and Effectiveness of ISIS 2922 in Patients With AIDS Who Have Cytomegalovirus (CMV) of the Eyes
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Registration Number
- NCT00002356
- Locations
- ๐บ๐ธ
UCI College of Medicine, Irvine, California, United States
๐บ๐ธEmory Univ School of Medicine / Emory Eye Ctr, Atlanta, Georgia, United States
๐บ๐ธHahnemann Univ Hosp, Philadelphia, Pennsylvania, United States
A Comparison of ISIS 2922 Used Immediately or Later in Patients With Cytomegalovirus (CMV) of the Eyes
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT00002355
- Locations
- ๐บ๐ธ
Dr Julio Perez, Fort Lauderdale, Florida, United States
๐บ๐ธUniv of Texas Southwestern Med Ctr of Dallas, Dallas, Texas, United States
๐บ๐ธUniv of Illinois, Chicago, Illinois, United States
A Randomized Comparison of Intravitreal ISIS 2922 Plus Ganciclovir Versus Ganciclovir as Treatment for Patients With Cytomegalovirus Retinitis ( CMVR )
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Target Recruit Count
- 194
- Registration Number
- NCT00002156
- Locations
- ๐บ๐ธ
Univ of Texas Southwestern Med Ctr of Dallas, Dallas, Texas, United States
๐บ๐ธRetina - Vitreous Associates Med Group, Los Angeles, California, United States
๐บ๐ธUniv of Illinois, Chicago, Illinois, United States
A Study of ISIS 2922 in the Treatment of Advanced Cytomegalovirus Retinitis
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Ionis Pharmaceuticals, Inc.
- Registration Number
- NCT00002187
- Locations
- ๐บ๐ธ
Retina - Vitreous Associates Med Group, Los Angeles, California, United States
๐บ๐ธNovum Inc, Seattle, Washington, United States
๐บ๐ธDr Julio Perez, Fort Lauderdale, Florida, United States